Lextrasa

Mesalazine, the active ingredient in Lextrasa, is an aminosalicylate presented as an oral formulation for oral use. It treats ulcerative colitis and mild to moderate Crohn's disease in adult patients.

GNH USA supplies Lextrasa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution.

Lextrasa (mesalazine) is used to manage inflammatory bowel disease by targeting intestinal inflammation.

Ulcerative colitis: induces and maintains remission of mild to moderate disease. Crohn's disease: reduces symptoms in mild to moderate disease involving the colon. Maintenance therapy: helps prevent relapse in ulcerative colitis. Induction of remission: facilitates symptom control during active ulcerative colitis flares.

Common Side Effects: - Nausea - Abdominal pain or cramping - Headache - Flatulence or increased gas - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Blood disorders such as leukopenia or thrombocytopenia - Elevated liver enzymes or hepatitis - Pancreatitis - Interstitial nephritis or renal impairment - Severe colitis or worsening of bowel symptoms

Precautions should be observed when prescribing mesalazine.

Monitor renal function: assess kidney parameters before and during therapy. Monitor hepatic function: check liver enzymes periodically. Assess disease activity: ensure appropriate disease severity before initiation. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Use with caution in sulfonamide‑allergic patients: consider alternative therapy. Store at room temperature: keep in the original pack, protect from moisture and excessive heat.

Mesalazine may interact with several medicines.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Azathioprine: heightened risk of bone marrow suppression. - Live vaccines: reduced vaccine efficacy and potential infection.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive effectiveness.